R306465 is developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Last reviewed 2026-04-19 · How we verify

R306465

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Phase 1 active Small molecule

At a glance

Generic name	R306465
Sponsor	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

R306465 CI brief — competitive landscape report
R306465 updates RSS · CI watch RSS
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI